E-Cigarettes and Heated Tobacco Associated with Higher Crohn's Recurrence Risk Post-Surgery

For Crohn's disease patients weighing surgical options, the assumption that switching from cigarettes to electronic or heated tobacco products reduces disease risk may be dangerously optimistic. A large multicenter study now provides the clearest evidence yet that these 'reduced-harm' alternatives carry meaningful consequences for gut inflammation after bowel resection.

Across nine centers in Italy, Spain, and France, 937 patients with Crohn's disease who underwent ileocolic resection were followed with endoscopic evaluation within one year of surgery. Patients were stratified by post-surgical smoking behavior: nonsmokers (74%), conventional cigarette smokers (19%), heat-not-burn tobacco (HNBT) users (4%), and e-cigarette users (4%). Endoscopic recurrence, defined by a Rutgeerts score of ≥2, occurred in 40.8% of nonsmokers — but in 69.4%, 63.9%, and 60.6% of traditional cigarette, HNBT, and e-cigarette users respectively. Crucially, elevated recurrence persisted even among patients receiving pharmacological prophylaxis, suggesting these products can override standard preventive treatment.

This finding challenges the public health framing of e-cigarettes and HNBT as harm-reduction tools, at least in the context of inflammatory bowel disease. Prior research has established that conventional tobacco smoke promotes intestinal inflammation through oxidative stress, immune dysregulation, and altered mucosal microbiome composition. What this study suggests is that nicotine itself — or other shared constituents across tobacco delivery formats — may be a principal driver of postoperative Crohn's recurrence, independent of combustion byproducts. The retrospective design limits causal inference, and the HNBT and e-cigarette cohorts were relatively small (37 and 33 patients), which constrains statistical precision for those subgroups. Nonetheless, the consistency of effect across all non-conventional smoking categories, and the fact that recurrence elevated even under pharmacological coverage, strengthens the signal considerably. For gastroenterologists managing surgical Crohn's patients, this multinational dataset represents a clinically meaningful increment over prior single-center evidence and warrants integration into post-operative counseling discussions.